Nektar Therapeutics

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 41.03, 36.91, 46.57, 75.47, 230.25 ], "ebit_estimate": [ -233.24, -351.26, -405.16, -440.53, -378.52 ], "ebitda_estimate": [ -240.95, -380.96, -418.93, null, null ], "net_income_estimate": [ -250.03, -355.79, -408.62, -454.15, -472.01 ], "per_share_eps_estimate": [ -9.01, -11.08, -11.7, -13.12, -10.66 ], "eps_nri_estimate": [ -9.06, -11.07, -11.4, -10.82, -10.15 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 5.7, 6, null, null, null ], "pretax_income_estimate": [ -246.28, -362.11, -408.51, -454.15, -472.01 ], "operating_cash_flow_per_share_estimate": [ -8.35, -8.95, null, null, null ], "roa_estimate": [ -90.2, -123.9, null, null, null ], "roe_estimate": [ -60.89, -53.5, -49, null, null ], "gross_margin_estimate": [ 100, 75, 75, 95, 95 ], "operating_cash_flow_estimate": [ -206.55, -221.39, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -6.99, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -7.89, "future_eps_nri_estimate_growth": -6.99, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -43.26, "future_ebitda_estimate_growth": -45.73, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -36.21, "future_pretax_income_estimate_growth": -38.87, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -151.19, "future_gross_margin_estimate_growth": -10.87, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 10.38, 10.18, 10.34, 10.77, 10.67, 10.74, 10.72, 10.68 ], "ebit_estimate": [ -53.45, -44.19, -76.3, -82.74, -81.21, -83.82, -86.55, null ], "ebitda_estimate": [ -49.64, -64.92, -87.49, -90.9, null, null, null, null ], "net_income_estimate": [ -58.55, -47.32, -79.62, -86.13, -85.54, -88.31, -91.18, null ], "per_share_eps_estimate": [ -2.07, -1.46, -2.69, -2.95, -2.64, -2.97, -2.94, null ], "eps_nri_estimate": [ -2.04, -1.51, -2.68, -2.92, -2.64, -2.97, -2.94, -3.65 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -56.71, -44.28, -79.97, -92.69, -97.39, -102.22, -107.26, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ -30.73, -31.6, -44.38, -52.22, null, null, null, null ], "gross_margin_estimate": [ 65, 70, 70, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": -6.99, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -7.89, "future_eps_nri_estimate_growth": -6.99, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -43.26, "future_ebitda_estimate_growth": -45.73, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -36.21, "future_pretax_income_estimate_growth": -38.87, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -151.19, "future_gross_margin_estimate_growth": -10.87, "future_operating_cash_flow_per_share_estimate_growth": null }